The Native Antigen Company 2023 Southern Hemisphere flu season antigens

Wednesday, 16 November, 2022 | Supplied by: BioNovus Life Sciences


In February and September of each year, the World Health Organization (WHO) convenes with its network of advisors to decide on flu vaccine formulations for the Northern and Southern Hemispheres, respectively. To support ongoing vaccine reformulation programs, The Native Antigen Company develops season-specific antigens to support vaccine and diagnostic manufacturers.

The company has announced that haemagglutinin (HA) and neuraminidase (NA) antigens are now available to cover the 2023 Southern Hemisphere vaccine formulation. Available in multiple vial sizes and in bulk quantities, antigens can be used in a range of applications, including immunoassay development and as immunogens.

Expressed using Native Antigen’s VirtuE HEK293 expression system, the antigens are designed to exhibit proper glycosylation and folding. The latest haemagglutinin antigens feature C-terminal T4 foldon domains, stabilising them in their trimeric conformation to present more native-like conformational epitopes.

Online: www.bionovuslifesciences.com.au
Phone: 02 9484 0931
Related Products

Amsbio BioPORTER Protein Delivery Reagent

The BioPORTER Protein Delivery Reagent from Amsbio is a specialised, lipid-based reagent designed...

Amsbio StemFit Basic04CT stem cell medium

StemFit Basic04CT from Amsbio is an animal-origin-free, defined, ready-to-use medium designed to...

Takara Bio Europe Cellartis MSC EV Wonder GMP-grade medium

Takara Bio Europe has introduced a Good Manufacturing Practice (GMP)-grade version of Cellartis...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd